Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Research Reveals Strong 13.5% CAGR Outlook Through 2030

The prostate-specific membrane antigen (PSMA) theranostic kits market is gaining significant attention as advancements in precision oncology continue to evolve. With a growing focus on targeted prostate cancer diagnosis and treatment, this sector is set to experience remarkable growth in the coming years. Below is an overview of the market's current valuation, key players, emerging trends, and detailed segment insights.

Market Valuation and Growth Trajectory for PSMA Theranostic Kits
The market for PSMA theranostic kits is projected to expand rapidly, reaching a valuation of $1.99 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 13.5%. Several factors contribute to this positive outlook, including an increasing preference for personalized cancer therapies, heightened investment in theranostic technologies, the expansion of nuclear medicine capabilities, and broader use of precision diagnostics in oncology. Furthermore, regulatory approvals for targeted treatments and the integration of imaging with therapeutic workflows are expected to reinforce market expansion. Key trends anticipated in this period include the widespread adoption of radioligand therapies, enhanced use of PSMA-based diagnostic tools, and a growing emphasis on companion diagnostics.

The prostate-specific membrane antigen (psma) theranostic kits market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rising incidence of prostate cancer, advancements in nuclear medicine imaging, increasing adoption of molecular diagnostics, early clinical validation of psma targeting, expansion of oncology research programs.

Download a free sample of the prostate-specific membrane antigen (psma) theranostic kits market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30362&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Shaping the PSMA Theranostic Kits Industry
The PSMA theranostic kits market features several prominent players driving innovation and growth. Notable companies include Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha-9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., and Blue Earth Diagnostics.
In a recent development, Germany-based Ariceum Therapeutics GmbH acquired UK-based Theragnostics Ltd. in June 2023. This strategic move is aimed at strengthening Ariceum's capabilities in PSMA-targeted theranostics and broadening its prostate cancer imaging portfolio. Theragnostics Ltd. specializes in developing the 68Ga THP PSMA diagnostic kits used for precise prostate cancer imaging.

Key Trends Influencing the Future of the PSMA Theranostic Kits Market
Innovation remains at the core of the PSMA theranostic kits market, with companies concentrating on developing advanced PSMA-targeted radioligand kits. These kits combine ligands that attach specifically to PSMA with radioactive isotopes to facilitate both diagnostic imaging and targeted treatment of prostate cancer.
For example, in March 2025, Telix Pharmaceuticals Limited from Australia introduced Illuccix, a novel kit designed for preparing Gallium-68 gozetotide injections. This product allows medical facilities to label the radionuclide immediately before administration, enhancing PET imaging of PSMA-positive prostate cancer lesions. Illuccix boasts features such as a ready-to-use preparation format, rapid imaging capability, disease-specific targeting, and compatibility with theranostic workflows. This advancement improves detection of metastatic lesions, aids in treatment planning, and supports therapy monitoring, creating a valuable alternative to traditional imaging and non-targeted therapies.

View the full prostate-specific membrane antigen (psma) theranostic kits market report:
https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Detailed Segmentation of the PSMA Theranostic Kits Market
The PSMA theranostic kits market is segmented across several dimensions to provide comprehensive insights:

1. Product Type:
- Diagnostic Kits
- Therapeutic Kits
- Combined Theranostic Kits

2. Application:
- Prostate Cancer
- Other Cancers

3. End-User:
- Hospitals
- Diagnostic Centers
- Research Institutes
- Specialty Clinics
- Other End-Users

Further subcategories within these segments include:

Diagnostic Kits such as PSMA Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, and Liquid Biopsy Kits.
Therapeutic Kits comprising Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, and Small Molecule Therapy Kits.
Combined Theranostic Kits including Integrated Imaging and Therapy Kits, Dual-Function Radiopharmaceutical Kits, PSMA Ligand-Based Theranostic Kits, and Personalized Treatment Kits.

This detailed breakdown illustrates the diversity and specialization within the PSMA theranostic kits market, reflecting the multifaceted approach to prostate cancer diagnosis and treatment.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.